Maximum Androgen Blockade Using LHRH Agonist Buserelin in Combination with Short-Term (Two Weeks) or Long-Term (Continuous) Cyproterone Acetate Is Not Superior to Standard Androgen Deprivation in the Treatment of Advanced Prostate Cancer

Prostate–Specific Antigen Levels and Clinical Response to Flutamide as the Second Hormone Therapy for Hormone–Refractory Prostate Carcinoma

“…The European Association of Urology reported the results of two contrasting studies. EORTC GU Trial 30853 demonstrated the efficacy of MAB [11], and EORTC GU Trial 30843 revealed no significant value for MAB [12]. However, a definitive conclusion concerning MAB remains to be obtained.…”

Maximal Androgen Blockade: Final Analysis of EORTC Phase III Trial 30853

“…In these studies, no long-term benefit has been observed with MAB [7, 8, 9, 10]. The question remains as to whether these differences are due to the use of cyproterone acetate or to a difference in prognostic factors.…”

Integrating Biomedical Knowledge to Model Pathways of Prostate Cancer Progression

“…Although this process can occur rapidly after an extended period of disease remission, progression to hormone-resistant cancer is nearly inevitable, occurs at a median of 18-24 months, and is associated with median time to mortality of two to three years. 84,85 These factors limit the number of samples of hormone-naïve tumors and complicate profiling changes in hormone sensitivity. To overcome the limitation of sample size, MCM analysis of hormone-naïve patients from multiple studies detected two interaction networks centered on protein biosynthesis and proliferation.…”